Rhinomed Valuation

Is RHNM.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of RHNM.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate RHNM.F's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate RHNM.F's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RHNM.F?

Key metric: As RHNM.F is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for RHNM.F. This is calculated by dividing RHNM.F's market cap by their current revenue.
What is RHNM.F's PS Ratio?
PS Ratio	1.4x
Sales	AU$8.05m
Market Cap	AU$11.51m

RHNM.F key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2.1x
Enterprise Value/EBITDA	-2x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does RHNM.F's PS Ratio compare to its peers?

The above table shows the PS ratio for RHNM.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	11.1x
SHWZ Medicine Man Technologies	0.05x	6.0%	US$8.0m
JAGX Jaguar Health	1.1x	34.8%	US$11.7m
ALID Allied	34.9x	n/a	US$3.4m
LYRA Lyra Therapeutics	8.5x	61.6%	US$12.4m
RHNM.F Rhinomed	1.4x	n/a	US$11.5m

Price-To-Sales vs Peers: RHNM.F is good value based on its Price-To-Sales Ratio (1.4x) compared to the peer average (13.1x).

Price to Sales Ratio vs Industry

How does RHNM.F's PS Ratio compare vs other companies in the US Pharmaceuticals Industry?

70 Companies	Price / Sales	Estimated Growth	Market Cap
OGN Organon	0.6x	-0.06%	US$4.12b
PRGO Perrigo	0.9x	3.4%	US$3.93b
BHC Bausch Health Companies	0.3x	1.5%	US$2.99b
AMRX Amneal Pharmaceuticals	1x	5.6%	US$2.59b

70 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: RHNM.F is good value based on its Price-To-Sales Ratio (1.4x) compared to the US Pharmaceuticals industry average (3.4x).

Price to Sales Ratio vs Fair Ratio

What is RHNM.F's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RHNM.F PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	1.4x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate RHNM.F's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Collegium Pharmaceutical

US$1.0b

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$30.71

2.4%

20.0%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$59.39

7.8%

20.6%

Teva Pharmaceutical Industries

US$18.8b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEVA

US$16.57

-2.7%

71.0%